Evidence map›Paper›PMID 41697477›Full record

ArticleClinical and experimental medicine2026

MLANA is a potential prognostic biomarker and correlated with immune infiltration in skin cutaneous melanoma.

Nan Tang, Xudong Lai, Weilun Wen, Yanhua Wu, Xifeng Xiong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nan TangDepartment of Traditional Chinese Medicine, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, 510220, China.
Xudong LaiDepartment of Infectious Disease, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, 510220, China.
Weilun WenDepartment of Traditional Chinese Medicine, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, 510220, China.
Yanhua WuDepartment of Traditional Chinese Medicine, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, 510220, China.
Xifeng XiongGuangzhou Institute of Traumatic Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, 510220, China. xifengxiong@ext.jnu.edu.cn.

Funding

Guangzhou Regional Major Scientific and Technological Project on Traditional Chinese Medicine-Young Scientist Program 2025QN016Guangzhou Science and Technology Project 2024A03J0662Guangzhou Science and Technology Project 2024A03J0672Guangzhou Science and Technology Project 2025A03J3363Guangzhou Science and Technology Project 2025A03J3364Guangzhou Traditional Chinese Medicine and Integrated Traditional Chinese and Western Medicine Project 20232A011007Guangzhou Traditional Chinese Medicine and Integrated Traditional Chinese and Western Medicine Project 20242A011014National Science Foundation of Guangdong 2021A1515012547 and 2023A1515011701
6 · The paper itself

Abstract

Skin cutaneous melanoma (SKCM) is an aggressive and life-threatening skin cancer arising from the malignant transformation of melanocytes. The incidence has risen in recent decades, significantly impacting patients’ quality of life and straining healthcare systems. Existing prognostic biomarkers for SKCM are not accurate enough, emphasizing the urgent need for new biomarkers and therapeutic targets. This study comprehensively explored the role of Melan-A (MLANA) in SKCM through bioinformatics analysis and in-vitro experiments. Results showed that MLANA is overexpressed in SKCM tissues, significantly linked to Breslow depth, and associated with poor patient prognosis. Functional assays revealed that interfering with MLANA expression inhibits melanoma cell proliferation, migration, and invasion, while inducing apoptosis and G1/S phase arrest. Immune infiltration analysis revealed a negative correlation between high MLANA expression and the infiltration levels of various immune cells, indicating that MLANA may facilitate SKCM progression by altering the tumor microenvironment. The study highlights MLANA’s biological importance in SKCM, suggesting its potential as a prognostic biomarker and immunotherapy target, thereby providing new insights for SKCM diagnosis and treatment.

Indexed as

Biomarkers, TumorMelanomaSkin NeoplasmsApoptosisCell Line, TumorCell MovementCell ProliferationCutaneous Malignant MelanomaFemaleGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, TumorImmune infiltrationMLANAPrognostic biomarkerSkin cutaneous melanoma

Identifiers

PMID41697477
PMCPMC12909343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.